A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching
The aim of this study is to evaluate whether the targeted hemoglobin increment (2 grams per decilitre) in the patient can be predicted from the hemoglobin dose/weight of the blood bag transfused. In the test group, the hemoglobin dose needed will be calculated, whereas in the control group, the prescribed number of red cell units will be transfused.
Hypothesis: By matching the hemoglobin dose to the individual needs of the patient the investigators will reduce the total usage of red cell concentrates.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
|Official Title:||A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching|
- Hemoglobin value [ Time Frame: Less than 24 hours before transfusion and immediately after transfusion ]The investigators measure the hemoglobin levels before and after transfusion to see if the hemoglobin increment is as expected from the amount of red cells given.
|Study Start Date:||November 2010|
|Estimated Study Completion Date:||June 2021|
|Estimated Primary Completion Date:||December 2020 (Final data collection date for primary outcome measure)|
Experimental: Hemoglobin dose
The subjects in this group receive an amount red blood cells that has been calculated from the patients' body surface area (BSA).
Other: Red blood cells (RBCs)
The subjects receive an amount of RBCs that has been calculated from their BSA.
Active Comparator: Standard treatment
The subjects in this group receive the prescribed number of red cell units.
Other: Red blood cells
The subjects in this group receive the prescribed number of redd blood cell units.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01328262
|Haukeland University Hospital|
|Principal Investigator:||Tor A Hervig, Professor|